239 related articles for article (PubMed ID: 25784176)
1. 3,6-Dihydroxyflavone Suppresses Breast Carcinogenesis by Epigenetically Regulating miR-34a and miR-21.
Peng X; Chang H; Gu Y; Chen J; Yi L; Xie Q; Zhu J; Zhang Q; Mi M
Cancer Prev Res (Phila); 2015 Jun; 8(6):509-17. PubMed ID: 25784176
[TBL] [Abstract][Full Text] [Related]
2. 3,6-Dihydroxyflavone regulates microRNA-34a through DNA methylation.
Peng X; Chang H; Chen J; Zhang Q; Yu X; Mi M
BMC Cancer; 2017 Sep; 17(1):619. PubMed ID: 28870206
[TBL] [Abstract][Full Text] [Related]
3. MicroRNA-34a and microRNA-21 play roles in the chemopreventive effects of 3,6-dihydroxyflavone on 1-methyl-1-nitrosourea-induced breast carcinogenesis.
Hui C; Yujie F; Lijia Y; Long Y; Hongxia X; Yong Z; Jundong Z; Qianyong Z; Mantian M
Breast Cancer Res; 2012 May; 14(3):R80. PubMed ID: 22616882
[TBL] [Abstract][Full Text] [Related]
4. Ampelopsin suppresses breast carcinogenesis by inhibiting the mTOR signalling pathway.
Chang H; Peng X; Bai Q; Zhou Y; Yu X; Zhang Q; Zhu J; Mi M
Carcinogenesis; 2014 Aug; 35(8):1847-54. PubMed ID: 24861637
[TBL] [Abstract][Full Text] [Related]
5. MicroRNA-152 targets DNA methyltransferase 1 in NiS-transformed cells via a feedback mechanism.
Ji W; Yang L; Yuan J; Yang L; Zhang M; Qi D; Duan X; Xuan A; Zhang W; Lu J; Zhuang Z; Zeng G
Carcinogenesis; 2013 Feb; 34(2):446-53. PubMed ID: 23125218
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of DNA methyltransferase as a novel therapeutic strategy to overcome acquired resistance to dual PI3K/mTOR inhibitors.
Qian XJ; Li YT; Yu Y; Yang F; Deng R; Ji J; Jiao L; Li X; Wu RY; Chen WD; Feng GK; Zhu XF
Oncotarget; 2015 Mar; 6(7):5134-46. PubMed ID: 25762617
[TBL] [Abstract][Full Text] [Related]
7. IGF-I induces upregulation of DDR1 collagen receptor in breast cancer cells by suppressing MIR-199a-5p through the PI3K/AKT pathway.
Matà R; Palladino C; Nicolosi ML; Lo Presti AR; Malaguarnera R; Ragusa M; Sciortino D; Morrione A; Maggiolini M; Vella V; Belfiore A
Oncotarget; 2016 Feb; 7(7):7683-700. PubMed ID: 26655502
[TBL] [Abstract][Full Text] [Related]
8. Novel Hsp90 inhibitor FW-04-806 displays potent antitumor effects in HER2-positive breast cancer cells as a single agent or in combination with lapatinib.
Huang W; Wu QD; Zhang M; Kong YL; Cao PR; Zheng W; Xu JH; Ye M
Cancer Lett; 2015 Jan; 356(2 Pt B):862-71. PubMed ID: 25449780
[TBL] [Abstract][Full Text] [Related]
9. MicroRNA 100 sensitizes luminal A breast cancer cells to paclitaxel treatment in part by targeting mTOR.
Zhang B; Zhao R; He Y; Fu X; Fu L; Zhu Z; Fu L; Dong JT
Oncotarget; 2016 Feb; 7(5):5702-14. PubMed ID: 26744318
[TBL] [Abstract][Full Text] [Related]
10. Methylated urolithin A, the modified ellagitannin-derived metabolite, suppresses cell viability of DU145 human prostate cancer cells via targeting miR-21.
Zhou B; Wang J; Zheng G; Qiu Z
Food Chem Toxicol; 2016 Nov; 97():375-384. PubMed ID: 27725205
[TBL] [Abstract][Full Text] [Related]
11. 3,6-dihydroxyflavone suppresses the epithelial-mesenchymal transition in breast cancer cells by inhibiting the Notch signaling pathway.
Chen J; Chang H; Peng X; Gu Y; Yi L; Zhang Q; Zhu J; Mi M
Sci Rep; 2016 Jun; 6():28858. PubMed ID: 27345219
[TBL] [Abstract][Full Text] [Related]
12. AC1MMYR2, an inhibitor of dicer-mediated biogenesis of Oncomir miR-21, reverses epithelial-mesenchymal transition and suppresses tumor growth and progression.
Shi Z; Zhang J; Qian X; Han L; Zhang K; Chen L; Liu J; Ren Y; Yang M; Zhang A; Pu P; Kang C
Cancer Res; 2013 Sep; 73(17):5519-31. PubMed ID: 23811941
[TBL] [Abstract][Full Text] [Related]
13. Delphinidin-3-glucoside suppresses breast carcinogenesis by inactivating the Akt/HOTAIR signaling pathway.
Yang X; Luo E; Liu X; Han B; Yu X; Peng X
BMC Cancer; 2016 Jul; 16():423. PubMed ID: 27388461
[TBL] [Abstract][Full Text] [Related]
14. MicroRNA-105 suppresses cell proliferation and inhibits PI3K/AKT signaling in human hepatocellular carcinoma.
Shen G; Rong X; Zhao J; Yang X; Li H; Jiang H; Zhou Q; Ji T; Huang S; Zhang J; Jia H
Carcinogenesis; 2014 Dec; 35(12):2748-55. PubMed ID: 25280563
[TBL] [Abstract][Full Text] [Related]
15. Honokiol activates LKB1-miR-34a axis and antagonizes the oncogenic actions of leptin in breast cancer.
Avtanski DB; Nagalingam A; Bonner MY; Arbiser JL; Saxena NK; Sharma D
Oncotarget; 2015 Oct; 6(30):29947-62. PubMed ID: 26359358
[TBL] [Abstract][Full Text] [Related]
16. miR-222 induces Adriamycin resistance in breast cancer through PTEN/Akt/p27
Wang DD; Yang SJ; Chen X; Shen HY; Luo LJ; Zhang XH; Zhong SL; Zhao JH; Tang JH
Tumour Biol; 2016 Nov; 37(11):15315-15324. PubMed ID: 27699665
[TBL] [Abstract][Full Text] [Related]
17. Ridaforolimus (MK-8669) synergizes with Dalotuzumab (MK-0646) in hormone-sensitive breast cancer.
Becker MA; Hou X; Tienchaianada P; Haines BB; Harrington SC; Weroha SJ; Sathyanarayanan S; Haluska P
BMC Cancer; 2016 Oct; 16(1):814. PubMed ID: 27765027
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt Activity.
deGraffenried LA; Friedrichs WE; Russell DH; Donzis EJ; Middleton AK; Silva JM; Roth RA; Hidalgo M
Clin Cancer Res; 2004 Dec; 10(23):8059-67. PubMed ID: 15585641
[TBL] [Abstract][Full Text] [Related]
19. HSP90 inhibitor AUY922 abrogates up-regulation of RTKs by mTOR inhibitor AZD8055 and potentiates its antiproliferative activity in human breast cancer.
Chen SM; Guo CL; Shi JJ; Xu YC; Chen Y; Shen YY; Su Y; Ding J; Meng LH
Int J Cancer; 2014 Nov; 135(10):2462-74. PubMed ID: 24706460
[TBL] [Abstract][Full Text] [Related]
20. Quercetin suppresses the mobility of breast cancer by suppressing glycolysis through Akt-mTOR pathway mediated autophagy induction.
Jia L; Huang S; Yin X; Zan Y; Guo Y; Han L
Life Sci; 2018 Sep; 208():123-130. PubMed ID: 30025823
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
